Clinical trials: Invasive Candidiases
Candida, Candidiasis
Anidulafungin Versus Fluconazole in the Treatment of Candidemia
Fluconazole is an FDA-approved drug that is widely used to treat fungal infections due to candida. The experimental drug anidulafungin has been found to be active in treating life-threatening fungal infections.
- Trial name
- NCT00058682
- Testing
- Anidulafungin
- Where
- United States
- Volunteers
- 248 people
- Sponsor
- National Cancer Institute (NCI)
Candidiasis, Cryptococcosis
A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections
The purpose of this study is to evaluate the efficacy and safety of Vfend for the treatment of fungal infections
- Conditions
- Candidiasis, Cryptococcosis, Aspergillosis
- Trial name
- NCT00647907
- Testing
- Voriconazole
- Where
- 4 sites in Taiwan
- Volunteers
- 7 people
- Sponsor
- Pfizer
Invasive Candidiasis
Comparison of Uncomplicated Candidemia Therapy Duration in Children
The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia. The specific aims are: Compare the desirability of outcome ranking in children with uncomplicated candidemia…
- Trial name
- COUNT (NCT05763251)
- Testing
- therapy duration
- Where
- 22 sites in United States, Australia
- Volunteers
- 420 people
- Sponsor
- Arkansas Children's Hospital Research Institute
Candidemia
Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis
Prospective, open label study to assess the pharmacokinetics, safety \& efficacy of anidulafungin when used to treat children (aged 1 month - <18 years) with invasive candidiasis, including candidemia (ICC).
- Trial name
- NCT00761267
- Testing
- Anidulafungin, Fluconazole
- Where
- 45 sites in United States, Brazil and 8 more
- Volunteers
- 70 people
- Sponsor
- Pfizer
Candidiasis
A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients
The purpose of this study is to determine whether voriconazole is safe and effective for the treatment of serious Candida infection and Candida infection of the esophagus in children and adolescents.
- Trial name
- NCT01092832
- Testing
- voriconazole
- Where
- 14 sites in China, Czechia and 6 more
- Volunteers
- 23 people
- Sponsor
- Pfizer
Nosocomial Infections, Sepsis
Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants
The purpose of this study is to show whether Veronate, a donor-selected staphylococcal human immune globulin intravenous (IGIV), can prevent an infection in the blood caused by staphylococcal bacteria in premature babies weighing…
- Conditions
- Nosocomial Infections, Sepsis, Staphylococcal Infections, Candidemia
- Trial name
- NCT00113191
- Testing
- Veronate
- Where
- 93 sites in United States, Canada
- Volunteers
- 2,000 people
- Sponsor
- Bristol-Myers Squibb
Candidiasis
Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis
The study will evaluate how effective and how safe the drug micafungin is when compared to the drug amphotericin B deoxycholate in treating neonates and young infants with certain fungal infections.
- Trial name
- MAGIC-2 (NCT00815516)
- Testing
- micafungin, amphotericin B deoxycholate
- Where
- 17 sites in United States, Brazil and 10 more
- Volunteers
- 30 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Invasive Candidiasis, Esophageal Candidiasis
Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
Infants and toddlers with fungal infections will receive 10 to 14 days of treatment with an antifungal drug. Safety and drug blood levels will be assessed
- Conditions
- Invasive Candidiasis, Esophageal Candidiasis, Oropharyngeal Candidiasis, Candidemia
- Trial name
- NCT00607763
- Testing
- Micafungin (Mycamine)
- Where
- 6 sites in United States
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Inc
Fever, Mycoses
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia
The objective of this study is to evaluate the safety, tolerance, and pharmacokinetics of FK463, a novel echinocandin (cell wall-active antifungal lipopeptide), as early empirical therapy for prevention of fungal infections in…
- Conditions
- Fever, Mycoses, Neutropenia
- Trial name
- NCT00001790
- Testing
- FK463
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Invasive Candidiases
ECMM Candida Registry - CandiReg
The objective of the European Confederation of Medical Mycology - ECMM Candida Registry (CandiReg) is to overcome the lack of knowledge on epidemiology, clinical course, and molecular characteristics of invasive infections due to…
- Trial name
- CandiReg (NCT03450005)
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- University of Cologne
Aspergillosis, Candidiasis
Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients
Fever and infection are serious complications of cancer treatment such as bone marrow transplant, especially when white blood cell counts are low.
- Conditions
- Aspergillosis, Candidiasis, Fungemia, Mycoses
- Trial name
- NCT00001937
- Testing
- FK463, Fluconazole
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- National Cancer Institute (NCI)
Candidiasis, Invasive
Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)
The study will evaluate the safety, tolerability, and efficacy of caspofungin as compared with amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and infants.
- Trial name
- NCT01945281
- Testing
- Caspofungin, Amphotericin B Deoxycholate
- Volunteers
- 51 people
- Sponsor
- Merck Sharp & Dohme LLC
Candidiasis
Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia
The purpose of this study is to determine the efficacy and safety of micafungin (FK463) versus liposomal amphotericin B (AmBisome) in treating neutropenic and non-neutropenic patients with confirmed invasive candidiasis or…
- Trial name
- NCT00106288
- Testing
- Micafungin, Liposomal Amphotericin B
- Where
- 37 sites in United States, Canada
- Volunteers
- 637 people
- Sponsor
- Astellas Pharma Inc
Invasive Candidiasis, Candidemia
Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia
To determine the efficacy and safety of micafungin (FK463) versus fluconazole (Diflucan) in treating patients with invasive candidiasis or candidaemia
- Trial name
- NCT00189709
- Testing
- Micafungin, fluconazole
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Inc
Mycoses
Voriconazole to Treat Fungal Infections
Voriconazole is a new drug developed to treat fungal infections. As of March 1999, the drug had been studied in more than 1,900 healthy volunteers or patients with fungal infections.
- Trial name
- NCT00001940
- Testing
- Voriconazole
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Mycoses
PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)
This phase II study will be conducted to: 1. evaluate the pharmacokinetics, safety, tolerance, and efficacy of different dosing schedules of Posaconazole in immunocompromised hosts with a variety of refractory invasive fungal…
- Trial name
- NCT00034671
- Testing
- Posaconazole oral suspension
- Volunteers
- 98 people
- Sponsor
- Merck Sharp & Dohme LLC
Candidiasis
The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis
Anidulafungin is a medicine being developed for treatment of patients with certain kinds of fungal infections. These infections due to yeast (a type of fungus) in the mouth/esophagus, in the blood or in other areas within the…
- Trial name
- NCT00056368
- Testing
- Anidulafungin, Fluconazole
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- Pfizer
Aspergillosis, Candidiasis
An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
The objective of this study is to evaluate the efficacy, safety and toleration of voriconazole in the primary treatment of systemic or invasive fungal infections due to fungal pathogens for which there is no licensed therapy; and…
- Conditions
- Aspergillosis, Candidiasis, Fungemia, Mycoses
- Trial name
- NCT00001810
- Testing
- Voriconazole
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute (NCI)
Pediatric Invasive Candidiasis
PEACE: Pediatric Antifungal Comparative Effectiveness
The overarching objective is to develop new evidence-based treatment guidelines for invasive fungal diseases in children. To accomplish that, this protocol will focus on two specific aims: 1) Compare the effectiveness of…
- Trial name
- PEACE (NCT01869829)
- Testing
- Observational antifungal therapy
- Where
- 35 sites in United States, Canada and 6 more
- Volunteers
- 750 people
- Sponsor
- Duke University
Candidiasis
Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers
The purpose of this study is to investigate the pharmacokinetics and safety of a fluconazole loading dose in infants and toddlers.
- Trial name
- NCT00797420
- Testing
- Fluconazole Loading Dose, Fluconazole Loading Dose & High Dose
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Daniel Benjamin